Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

73.02 USD +0.17 (+0.23%)
Streaming Delayed Price Updated: 12:43 PM EST, Mar 3, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
79 80 Next >
Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801
Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801 
From Business Wire News Releases
IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2
IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2 
From Business Wire News Releases
Merck to Acquire Themis
Merck to Acquire Themis 
From Business Wire News Releases
Merck to Announce Multiple Scientific Efforts to Combat COVID-19
Merck to Announce Multiple Scientific Efforts to Combat COVID-19 
From Business Wire News Releases
Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients
From GlobeNewswire News Releases
LYNPARZA® (olaparib) Approved by FDA for Treatment of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone
LYNPARZA Approved by FDA for Treatment of HRR Gene-Mutated mCRPC That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone 
From Business Wire News Releases
CORRECTING and REPLACING Merck Announces Appointment of Organon & Co. Chief Financial Officer and Chief Information Officer
Merck Announces Appointment of Organon & Co. Chief Financial Officer and Chief Information Officer 
From Business Wire News Releases
Infectious Disease Connect and ILÚM Health Solutions Combine to Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship
Infectious Disease Connect and ILÚM Health Solutions Combine to Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship 
From Business Wire News Releases
Merck to Present at the UBS Virtual Global Healthcare Conference
Merck to Present at the UBS Virtual Global Healthcare Conference 
From Business Wire News Releases
Merck’s KEYTRUDA® (pembrolizumab) Superior to Brentuximab Vedotin (BV), a Standard of Care, in Patients With Classical Hodgkin Lymphoma (cHL) in Head-to-Head Phase 3 Trial
Merck's KEYTRUDA Superior to Brentuximab Vedotin , a Standard of Care, in Patients with Classical Hodgkin Lymphoma in Head-to-Head Phase 3 Trial 
From Business Wire News Releases
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Chemotherapy in Certain Patients with Metastatic Triple-Negat
Merck’s KEYTRUDA Plus Chemotherapy Demonstrated Statistically Significant Improvement in PFS Versus Chemotherapy in Certain Patients with mTNBC 
From Business Wire News Releases
New Combination Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Clinical Benefit in Stage III Non-Small Cell Lung Cancer (NSCLC) and Reinforce Long-Term Survival in Metastatic NSCLC
New Combination Data for Merck’s KEYTRUDA Demonstrated Clinical Benefit in Stage III NSCLC and Reinforce Long-Term Survival in Metastatic NSCLC 
From Business Wire News Releases
Merck’s Novel HIF-2α Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with von Hippel-Lindau (VHL) Disease-Associated Clear Cell Renal Cell Carcinoma
Merck’s Novel HIF-2α Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with VHL Disease-Associated Clear Cell Renal Cell Carcinoma 
From Business Wire News Releases
Merck Animal Health to Acquire U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals
Merck Animal Health to Acquire U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals 
From Business Wire News Releases
LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer
LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer 
From Business Wire News Releases
Merck Announces Virtual 2020 Annual Shareholders Meeting
Merck Announces Virtual 2020 Annual Shareholders Meeting 
From Business Wire News Releases
Magic Mushrooms Could Be the Next Investment Trend
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Magic Mushrooms Could Be the Next Investment Trend
FN Media Group Presents Financialmorningpost.com Market Commentary 
From PR Newswire
Merck to Present at the BofA Securities 2020 Health Care Conference
Merck to Present at the BofA Securities 2020 Health Care Conference 
From Business Wire News Releases
Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program
Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program 
From Business Wire News Releases
Results of Phase 3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™ (Imipenem, Cilastatin, and Relebactam) Versus Piperacillin and Tazobactam in Adult Patients with HABP/VABP Now Availab
Results of Phase 3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™ Versus Piperacillin and Tazobactam in Adult Patients with HABP/VABP 
From Business Wire News Releases
Biotech Brief: Global Market For Cancer Drug Candidates Could Exceed US$220 Billion By 2025
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Biotech Brief: Global Market for Cancer Drug Candidates Could Exceed US$220 Billion by 2025
Financialnewsmedia.com News Commentary 
From PR Newswire
Merck Commits Additional $10 Million to COVID-19 Relief Efforts to Help Disparately Impacted Patients and Communities
Merck Commits Additional $10 Million to COVID-19 Relief Efforts to Help Disparately Impacted Patients and Communities 
From Business Wire News Releases
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Use at an Additional Recommended Dose of 400 mg Every Six Weeks for All Approved Adult Indications
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Use at an Additional Recommended Dose of 400 mg Every Six Weeks for All Approved Adult Indications 
From Business Wire News Releases
Merck Announces First-Quarter 2020 Financial Results
Merck Announces First-Quarter 2020 Financial Results 
From Business Wire News Releases
First Clinical Outcomes Evaluating Six-Week Dosing Schedule for Merck’s KEYTRUDA® (pembrolizumab) Presented at AACR Virtual Annual Meeting I
First Clinical Outcomes Evaluating Six-Week Dosing Schedule for Merck’s KEYTRUDA® (pembrolizumab) Presented at AACR Virtual Annual Meeting I 
From Business Wire News Releases
Merck and Institute for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2 Infection and Identify Potential Prognostic Biomarkers
Merck and Institute for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2 Infection & Identify Potential Prognostic Biomarkers 
From Business Wire News Releases
LYNPARZA® (olaparib) Demonstrated Overall Survival Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
LYNPARZA Demonstrated Overall Survival Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer 
From Business Wire News Releases
LYNPARZA® (Olaparib) Demonstrated Overall Survival Benefit in Phase III PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced further positive results from the Phase III PROfound trial of LYNPARZA (olaparib) in men with... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
79 80 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account